Journal of Osteoporosis

Research Article

Treatment for Osteoporosis among Women in Japan: Associations with Patient Characteristics and Patient-Reported Outcomes in the 2008–2011 Japan National Health and Wellness Surveys

Table 4

Unadjusted mean outcomes according to type of osteoporosis treatment.


	Raloxifene		Bisphosphonates		Active vitamin D₃ alone		Calcitonin alone		value¹
	()		()		()		()
	Mean	SD	Mean	SD	Mean	SD	Mean	SD

HRQoL (SF-12v2)
MCS	50.97	8.46	47.55	10.59	46.64	10.77	50.07	8.93	0.063
PCS	44.52	9.35	44.73	10.71	42.93	13.37	45.05	8.42	0.676
Health utility score (SF-6D)	0.745	0.139	0.718	0.141	0.703	0.151	0.756	0.135	0.163
Activity impairment (%)	28.91	27.26	32.38	29.15	34.50	29.08	31.09	28.85	0.788
6-month healthcare use
Physician visits	10.59	8.48	15.41	16.76	17.20	19.16	12.57	14.47	0.130
ER visits	0.09	0.35	0.32	2.06	0.37	1.63	0.15	0.51	0.796
Hospitalizations	2.09	11.20	1.91	9.32	2.10	8.74	3.39	18.02	0.855

¹One-way ANOVA; HRQoL: health-related quality of life; MCS: mental component summary; PCS: physical component summary; ER: emergency room.